latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/us-patent-board-upholds-teva-patents-on-migraine-drug-in-challenge-by-eli-lilly-57850745 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

US patent board upholds Teva patents on migraine drug in challenge by Eli Lilly

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


US patent board upholds Teva patents on migraine drug in challenge by Eli Lilly

The validity of Teva Pharmaceutical Industries Ltd.'s migraine drug patents was upheld by the appeal board of the U.S. Patent and Trademark Office, rejecting a challenge by Eli Lilly and Co.

The Patent Trial and Appeal Board's decision covers three patents related to Teva's migraine drug Ajovy.

The dispute between the companies arose when Petah Tikva, Israel-based Teva sued Eli Lilly in 2018, alleging the Indianapolis-based drugmaker's Emgality infringed on the three patents. Lilly responded by seeking an inter partes review of Teva's patents, arguing that they were unpatentable from the start.

The board ruled that Eli Lilly failed to prove its claims that the three patents were unpatentable.

Ajovy belongs to a group of medicines known as calcitonin gene-related peptide, or CGRP, inhibitors. Other CGRP inhibitors include Lilly's Emgality and Novartis AG's Aimovig.

In March, the U.K.'s National Institute for Health and Care Excellence recommended Ajovy as a cost-effective therapy for treating chronic migraine. The therapy is also approved in the U.S. and Europe.